Domov › Rakovina vaječníkov › Minnesota › Rochester
Klinické štúdie Rakovina vaječníkov v meste Rochester, MN
29 štúdií pre Rakovina vaječníkov hľadá účastníkov v zariadeniach v meste Rochester a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity
Prebieha náborFáza 2/3
- Mayo Clinic in Rochester, Rochester
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Prebieha náborFáza 2
- Mayo Clinic in Rochester, Rochester
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Prebieha náborObservačná štúdia
- Mayo Clinic, Rochester
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
Prebieha nábor
- Mayo Clinic, Rochester
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Prebieha náborObservačná štúdia
- Mayo Clinic Rochester, Rochester
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Prebieha náborFáza 1/2
- Mayo Clinic - Rochester, Rochester
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Prebieha náborFáza 3
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Prebieha náborFáza 1
- Mayo Clinic - Rochester, Rochester
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Prebieha náborFáza 1/2
- Mayo Rochester, Rochester
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Prebieha náborObservačná štúdia
- Mayo Clinic (Rochester), Rochester
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Prebieha nábor
- Mayo Clinic in Rochester, Rochester
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Prebieha náborFáza 3
- Mayo Clinic in Rochester, Rochester
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Mayo Clinic (Minnesota), Rochester
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
Prebieha náborFáza 3
- Mayo Clinic Methodist Campus, Rochester
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Prebieha náborFáza 2
- Mayo Clinic, Rochester
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
Prebieha náborFáza 1/2
- The Mayo Clinic, Rochester
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Prebieha náborFáza 1
- Mayo Clinic, Rochester
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Prebieha náborFáza 1/2
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Prebieha náborFáza 1/2
- Mayo Clinic - Rochester, Rochester
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Prebieha náborFáza 1/2
- Mayo Clinic Rochester, Rochester
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
Prebieha nábor
- Mayo Clinic, Rochester
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Prebieha náborFáza 3
- Mayo Clinic, Rochester
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Prebieha nábor
- Mayo Clinic, Rochester
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Prebieha náborFáza 1/2
- Mayo Clinic, Rochester
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
Prebieha náborFáza 1
- Mayo Clinic in Rochester, Rochester
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
Prebieha nábor
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Prebieha náborObservačná štúdiaVítaní zdravých dobrovoľníkov
- Mayo Clinic, Rochester
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Prebieha náborFáza 2
- Mayo Clinic, Rochester
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Prebieha náborFáza 1
- Exelixis Clinical Site #14, Rochester
Štúdie Rakovina vaječníkov v iných mestách
- Houston, TX89 štúdií
- New York City, NY69 štúdií
- Boston, MA61 štúdií
- Los Angeles, CA50 štúdií
- Nashville, TN49 štúdií
- Arlington, VA46 štúdií
- Philadelphia, PA44 štúdií
- Columbus, OH39 štúdií
- St. Louis, MO38 štúdií
- Chicago, IL36 štúdií
- San Antonio, TX31 štúdií
- Cleveland, OH30 štúdií
Iné štúdie v Rochester
- Rakovina prsníka42 štúdií
- Nemalobunkový karcinóm pľúc37 štúdií
- Metastatická rakovina31 štúdií
- Rakovina (všetky typy)30 štúdií
- Kolorektálny karcinóm29 štúdií
- Mnohonásobný myelóm24 štúdií
- Srdcové zlyhanie22 štúdií
- Rakovina prostaty22 štúdií
- Rakovina pankreasu22 štúdií
- Rakovina endometria20 štúdií
- Rakovina pľúc20 štúdií
- Chronická lymfocytová leukémia18 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.